Timothy S. Callahan

At Padagis our focus is on health care products that improve people’s lives. We are experts on extended topical products and are strategically investing to expand our #1 position in the extended topical category in the United States. Our team members, numbering more than 1,300 work in a dynamic environment where opportunity is built on a foundation of honesty and transparency.

CMP Pharma, Inc. is a pharmaceuticals company based out of 8026 US Highway 264A, Farmville, North Carolina, United States.

At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma

Altaris is an investment firm exclusively focused on the healthcare industry. We seek to build market-leading companies that deliver innovation and efficiency to the healthcare system, with the ultimate goal of improving access and outcomes for patients. Since inception in 2003, Altaris has invested in 50 healthcare companies which have generated significant value appreciation for investors. Altaris is headquartered in New York City and manages ~$10 billion of equity capital as of June 2024. For more information, please visit www.altariscap.com.

At Padagis our focus is on health care products that improve people’s lives. We are experts on extended topical products and are strategically investing to expand our #1 position in the extended topical category in the United States. Our team members, numbering more than 1,300 work in a dynamic environment where opportunity is built on a foundation of honesty and transparency.

OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

CMP Pharma, Inc. is a pharmaceuticals company based out of 8026 US Highway 264A, Farmville, North Carolina, United States.

At Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), we’re igniting change in gastrointestinal (GI) medicine to develop new treatments with the potential to improve the lives of patients. Our values guide every aspect of our business—our relationships with customers, our approach to science and innovation, and our vision of a healthier future for patients. For more than 20 years, our scientists have been relentlessly committed to developing differentiated therapies for the GI market. Since the late 1990s, we have been focused on pioneering the research and development of uroguanylin analogs, a naturally occurring human GI peptide, through our clinical work. Our goal is to develop innovative treatments that improve efficacy, safety and tolerability and deliver a better experience for patients living with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation (OIC), and ulcerative colitis (UC). We are committed to scientifically driven innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our customers. You can find us based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. Learn more about our company here: http://www.synergypharma.com/about-us You can also follow us on Twitter: @SynergyPharma